Home Cart Sign in  
Chemical Structure| 2326521-71-3 Chemical Structure| 2326521-71-3

Structure of Adagrasib
CAS No.: 2326521-71-3

Chemical Structure| 2326521-71-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Adagrasib (MRTX849) is a potent, orally available, mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. It binds covalently to the cysteine at residue 12 of KRAS G12C, locking the protein in its inactive GDP-bound conformation and inhibiting KRAS-dependent signal transduction.

Synonyms: MRTX849

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Morstein, Johannes ; Shrestha, Rebika ; Van, Que N. ; Lopez, Cesar A. ; Arora, Neha ; Tonelli, Marco , et al.

Abstract: Protein-membrane interactions (PMIs) are ubiquitous in cellular signaling. Initial steps of signal transduction cascades often rely on transient and dynamic interactions with the inner plasma membrane leaflet to populate and regulate signaling hotspots. Methods to target and modulate these interactions could yield attractive tool compounds and drug candidates. Here, the conjugation of a medium-chain lipid tail to the covalent K-Ras(G12C) binder MRTX849 at a solvent-exposed site enables such direct modulation of PMIs. The conjugated lipid tail interacts with the tethered membrane and changes the relative membrane orientation and conformation of K-Ras(G12C), as shown by mol. dynamics (MD) simulation-supported NMR studies. In cells, this PMI modulation restricts the lateral mobility of K-Ras(G12C) and disrupts nanoclusters. The described strategy could be broadly applicable to selectively modulate transient PMIs.

Purchased from AmBeed: ; ; ; ; ; ;

Alternative Products

Product Details of Adagrasib

CAS No. :2326521-71-3
Formula : C32H35ClFN7O2
M.W : 604.12
SMILES Code : N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C(CN(C4=C5C(Cl)=CC=CC5=CC=C4)CC3)=NC(OC[C@H]6N(C)CCC6)=N2)C1
Synonyms :
MRTX849
MDL No. :MFCD32263433
InChI Key :PEMUGDMSUDYLHU-ZEQRLZLVSA-N
Pubchem ID :138611145

Safety of Adagrasib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Adagrasib

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
NCI-H2122 150 nM 72 hours Evaluate the antiproliferative response of BI-3406 in combination with adagrasib Nat Cancer. 2024 Sep;5(9):1352-1370.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse KCL cell subcutaneous xenograft model Oral 100 mg/kg/d Once daily for 30 days Evaluate the in vivo effect of TNO155 in combination with MRTX-849 Cancer Res. 2023 Dec 15;83(24):4095-4111.
Mice KRAS-G12C mutant tumor model Oral gavage 35 mg/kg Twice a week for 3 to 6 weeks To evaluate the synergistic effect of DGY-06-116 with MRTX849 in vivo, results showed that the combination therapy significantly inhibited tumor growth and prolonged the survival of mice. Sci Adv. 2024 Dec 13;10(50):eadq4274

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05673187 NSCLC Stage IV|KRAS P.G12C PHASE2 RECRUITING 2026-03-01 Instiute Jules Bordet, Brussel... More >>s, Belgium|Centre Hospitalier d'Avignon, Avignon, France|Caen - CHU, Caen, France|Le Mans - CHG, Le Mans, France|H?pital de Marseille, Marseille, France|Beaumont Hospital, Dublin, Ireland|St James's Hospital, Dublin, Ireland|University Hospital Limerick, Limerick, Ireland|University Hospital Waterford, Waterford, Ireland|Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|Santa Maria della Misericordia Hospital, Perugia, Italy|Istituto Nazionale Tumori "Regina Elena", Rome, Italy|AULSS2 Marca Trevigiana Treviso, Treviso, Italy|Complejo Hospitalario Universitario a Coru?a, A Coru?a, Spain|Alicante University Hospital, Alicante, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Badalona, Spain|Hospital de Basurto, Bilbao, Spain|ICO Bellvitge -H. Duran i Reynals / H. Bellvitge, L'Hospitalet De Llobregat, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital General Universitario de Valencia (University Hospital Valencia), Valencia, Spain|Christie NHS Manchester, Manchester, United Kingdom Less <<
NCT05634525 Metastatic Pancreatic Cancer PHASE1 RECRUITING 2027-11-01 M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less <<
NCT06801418 Healthy Volunteers PHASE1 NOT_YET_RECRUITING 2025-05-30 Local Institution - 0003, Lene... More >>xa, Kansas, 66219-9746, United States|Local Institution - 0002, San Antonio, Texas, 78209-1028, United States|Local Institution - 0001, Salt Lake City, Utah, 84124-1365, United States Less <<
NCT05853575 Advanced Cancer|Metastatic Can... More >>cer|Malignant Neoplasm of Lung Less << PHASE2 RECRUITING 2025-03-31 Providence Medical Foundation,... More >> Santa Rosa, California, 95403, United States|Local Institution - 106, Chicago, Illinois, 60612, United States|Local Institution - 103, Minneapolis, Minnesota, 55417, United States|Local Institution - 105, Kansas City, Missouri, 64128, United States|Veterans Affairs Medical Center (VAMC) - Durham, Durham, North Carolina, 27705, United States|VA North Texas Healthcare System/Dallas VA Medical Center, Dallas, Texas, 75216-7167, United States|Local Institution - 179, Cachoeiro Do Itapemirim, Espírito Santo, 29308-065, Brazil|Local Institution - 178, Belo Horizonte, Minas Gerais, 30360680, Brazil|Local Institution - 177, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Local Institution - 182, Itajaí, Santa Catarina, 88301-220, Brazil|Local Institution - 181, Salvador, 41950-610, Brazil|Local Institution - 175, S?o Paulo, 01509-900, Brazil|Local Institution - 527, Zagreb, Grad Zagreb, 10000, Croatia|Local Institution - 525, Pula, 52100, Croatia|Hopital Haut-Leveque - Maladies respiratoires, Pessac, Gironde, 33604, France|Local Institution - 553, Saint-Herblain Cedex, Loire-Atlantique, 44800, France|Centre Hospitalier Universitaire D' Angers H?pital Larrey - PNEUMOLOGIE, Angers, Maine-et-Loire, 49933, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, Poitou-Charentes, 86000, France|Local Institution - 559, Grenoble, Rh?ne-Alpes, 0, France|Local Institution - 560, Villefranche Sur Saone, Rh?ne, 69655, France|Centre H?spitalier de Bretagne Sud - H?pital du Scorff, Lorient, 56322, France|APHM Hopital Nord, Marseille, 13915, France|CHU de Nantes - H?pital Nord La?nnec (HGRL), Nantes cedex 1, 44093, France|Local Institution - 558, Quimper, 29000, France|H?pital Bégin - Service d'Oncologie, Saint-Mandé, 94163, France|Local Institution - 577, Patras, Acha?a, 265 04, Greece|Local Institution - 575, Athens, Attiki, 11528, Greece|Local Institution - 582, Athens, Attiki, 11528, Greece|Local Institution - 579, Haidari - Athens, Attiki, 12462, Greece|Local Institution - 576, Thessaloniki, Kentriki Makedonia, 54639, Greece|Local Institution - 580, Panorama, 552 36, Greece|Local Institution - 581, Thessaloniki, 56429, Greece|Local Institution - 628, Tel Aviv-Yafo, Tel-Aviv, 64239, Israel|Local Institution - 625, Jerusalem, Yerushalayim, 9103102, Israel|Local Institution - 629, Haifa, 31048, Israel|Local Institution - 627, Haifa, 3109601, Israel|Local Institution - 626, Tel-Aviv, 6423906, Israel|Local Institution - 778, Pesaro, Pesaro E Urbino, 61122, Italy|Local Institution - 780, Candiolo, Torino, 10060, Italy|Local Institution - 779, Milano, 20141, Italy|Local Institution - 777, Novara, 28100, Italy|Local Institution - 775, Perugia, 6132, Italy|Local Institution - 776, Roma, 144, Italy|National Cancer Center, Gyeonggido [Kyonggi-do], Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 10408, Korea, Republic of|Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 6351, Korea, Republic of|Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 8308, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 6273, Korea, Republic of|Local Institution - 128, Tuxtla Gutiérrez, Chiapas, 29038, Mexico|Local Institution - 129, Cdmx, Distrito Federal, 3810, Mexico|Local Institution - 127, Col. Roma, Distrito Federal, 0, Mexico|Local Institution - 125, Toluca, 50090, Mexico|Local Institution - 802, Breda, Noord-Brabant, 4818 CK, Netherlands|Local Institution - 800, Amsterdam, Noord-Holland, 1066 CX, Netherlands|Local Institution - 801, Nieuwegein, Utrecht, 3435 CM, Netherlands|Local Institution - 650, Krakow, Malopolskie, 30-727, Poland|Local Institution - 651, Gdynia, Pomorskie, 81-519, Poland|Local Institution - 653, Lublin, 20-064, Poland|Local Institution - 732, Cluj-Napoca, Cluj, 400641, Romania|Local Institution - 731, Ovidiu, Constanta, 905900, Romania|Local Institution - 729, Craiova, Dolj, 200385, Romania|Local Institution - 734, Craiova, Dolj, 200542, Romania|Local Institution - 730, Timisoara, Timis, 300166, Romania|Local Institution - 733, Iasi, 700106, Romania|Local Institution - 725, Sibiu, 550245, Romania|Local Institution - 728, Suceava, 720214, Romania|Local Institution - 753, Belgrade, Beograd, 11000, Serbia|Local Institution - 754, Nis, Niaavski Okrug, 18000, Serbia|Local Institution - 752, Kragujevac, ?umadijski Okrug, 34000, Serbia|Complexo Hospitalario Universitario De Santiago, Santiago De Compostela, A Coru?a, 15706, Spain|Local Institution - 678, Malaga, Andalucía, 29010, Spain|Local Institution - 676, Oviedo, Asturias, 33011, Spain|Local Institution - 685, Palma de Mallorca, Baleares, 7120, Spain|Local Institution - 684, Valencia, Valenciana, Comunidad, 46026, Spain|Local Institution - 687, Barcelona, 8028, Spain|Local Institution - 681, Barcelona, 8035, Spain|Local Institution - 683, Barcelona, 8041, Spain|Local Institution - 675, Madrid, 28007, Spain|Local Institution - 679, Madrid, 28033, Spain|Hospital Universitario Virgen De La Macarena, Sevilla, 41009, Spain|Local Institution - 677, Valencia, 46010, Spain|Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsuing City, Kaohsiung, 83301, Taiwan|China Medical University Hospital - Internal Medicine, Taichung City, Taichung Municipality, 40447, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taichung, 40201, Taiwan|Local Institution - 355, Taichung City, Taichung, 40705, Taiwan|Local Institution - 377, Bangkok, Krung Thep Maha Nakhon [Bangkok], 10700, Thailand|Local Institution - 376, Chiang Mai, 50200, Thailand|Local Institution - 375, Khon Kaen, 40002, Thailand|Local Institution - 378, Songkhla, 90110, Thailand|Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi, Ankara, 6010, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, 6200, Turkey|Memorial Ankara Hastanesi Tibbi Onkoloji, Ankara, 6520, Turkey|Ankara Liv Hospital Tibbi Onkoloji, Ankara, 6680, Turkey|Ankara Bilkent Sehir Hastanesi Tibbi Onkoloji Klinigi, Ankara, 6800, Turkey|Trakya Univ Hastanesi Ic Hastal, Edirne, 22030, Turkey|Local Institution - 709, Istanbul, 34214, Turkey|Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey|Istanbul Onkoloji Hastanesi Tibbi Onkoloji, Istanbul, 34846, Turkey|Local Institution - 708, Izmir, 35100, Turkey Less <<
NCT05263986 Advanced or Metastatic Solid T... More >>umor Less << PHASE1 UNKNOWN 2023-10-31 Beijing Cancer Hospital, Beiji... More >>ng, Beijing, China|Chongqing University Cancer Hospital, Chongqing, Chongqing, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Union hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|The first Hospital of Jilin University, Changchun, Jilin, China|Lin Yi Cancer Hospital, Linyi, Shandong, China|Shanghai Chest Hospital, Shanghai, Shanghai, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.66mL

0.33mL

0.17mL

8.28mL

1.66mL

0.83mL

16.55mL

3.31mL

1.66mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories